Prolase

Prolase: A Papain-Based Proteolytic Enzyme Ingredient

Overview and Scope of This Article

Prolase is a trade or ingredient name appearing on dietary supplement labels in the United States, catalogued by the NIH Office of Dietary Supplements' Dietary Supplement Label Database (DSLD). The NIH Dietary Supplement Label Database (DSLD) is a searchable database of current and historical label information from products marketed in the U.S. Prolase is documented within that database as a supplement ingredient name; however, no independent peer-reviewed clinical literature, government health-body monograph (WHO, ESCOP, European Pharmacopoeia), or pharmacopeial standard exists that treats "Prolase" as a chemically distinct substance separate from the broader class of papain-derived or multi-enzyme proteolytic preparations to which it belongs.

The authoritative scientific and regulatory record — including assessments by the European Food Safety Authority (EFSA), the U.S. Food and Drug Administration (FDA), and peer-reviewed enzyme biochemistry literature — describes the underlying active material as a papain-containing cysteine endopeptidase complex derived from Carica papaya L. This article therefore presents the fully sourced evidence base for this class of ingredient, of which Prolase is a labeled preparation, clearly distinguishing traditional use from clinical evidence and characterizing the strength of evidence honestly throughout.

Identity and Chemical Characterization

Botanical Source and Taxonomy

The food enzyme papain (EC 3.4.22.2) is extracted from the latex of unripe Carica papaya L. Carica papaya L. (family Caricaceae), commonly known as papaya or pawpaw, is a tropical tree native to Central America and now widely cultivated throughout tropical and subtropical regions worldwide.

Papain is a plant-derived cysteine protease (~23.4 kDa) extracted from the latex of the papaya tree (Carica papaya) that digests protein substrates and has long uses in food processing, topical enzymatic wound debridement, and as an oral digestive enzyme supplement.

Enzyme Complex Composition

Papain-based preparations are not a single molecular entity but a complex of related cysteine endopeptidases. The food enzyme is a cysteine endopeptidase complex, containing papain (EC 3.4.22.2), chymopapain (EC 3.4.22.6), caricain (EC 3.4.22.30) and glycyl endopeptidase (EC 3.4.22.25), obtained from the latex of unripe Carica papaya L.

Within C. papaya, a spectrum of bioactive compounds were identified, encompassing alkaloids, tannins, phenolics, flavonoids, saponins, terpenoids, sugars, glycosides, amino acids, steroids, and the pivotal enzyme papain.

The papaya fruit (Carica papaya) contains several proteolytic enzymes (papain, chymopapain A, chymopapain B, and papaya peptidase A).

Enzyme Classification and Catalytic Mechanism

Papains catalyse the hydrolysis of proteins with broad specificity for peptide bonds. The enzyme belongs to the cysteine protease (thiol protease) family, a class defined by a catalytic cysteine residue at the active site. The broader enzymatic class, of which papain is the archetypal member, is denoted EC 3.4.22.

Proteolytic enzymes, also known as proteases, are natural substances found in the human body and certain plants that assist in digesting proteins. While the body primarily produces these enzymes in the pancreas, they can also be sourced from foods like papaya and pineapple, which contain the enzymes papain and bromelain.

Physical Source within the Plant

Papain and bromelain are naturally occurring serine proteases. Papain is derived from the latex from green papaya fruit (Carica papaya) while bromelain is obtained from pineapple stalks (Ananas comosus).

Papayas contain an enzyme called papain, also known as papaya proteinase I. Papain is found in the leaves, roots and fruit of the papaya plant. The highest concentration of papain is found in the latex of the unripe (green) fruit, which is tapped and collected for commercial enzyme production.

Common Preparations and Commercial Forms

Enzyme Development Corporation (EDC) was founded in 1953. Their first product, LIQUIPANOL® T-100, was a liquid Papain for chill proofing/clarifying beer and is still used for this application today. Papain use has also expanded into numerous food, nutritional supplements, animal feed, and industrial processing applications that require protein hydrolysis. EDC is the only producer of Papain in the western hemisphere. At their factory in Scranton, Pennsylvania, they produce PANOL®, LIQUIPANOL®, and ENZECO® standardized Papain powders and liquids, as well as unstandardized concentrates.

In the dietary supplement industry, papain-based preparations including those sold under names such as "Prolase" are commercially available in the following forms:

• Standardized dry powders — used in tablet and capsule manufacturing, standardized by enzymatic activity units (Papain Units, PU).
• Tablets (plain and chewable) — among the most common consumer supplement forms.
• Capsules (standard and delayed-release) — supplemental formulas that are "enteric coated" tablets or "delayed release" capsules may be absorbed best because the coating helps protect them from being broken down too early in the stomach.
• Combination enzyme blends — some supplements contain a single type of proteolytic enzyme, while others contain a combination. Bromelain, papain, pancreatin, trypsin and chymotrypsin are proteolytic enzymes that are commonly added to proteolytic supplement blends.
• Topical ointments and wound dressings — for enzymatic debridement (discussed below under clinical evidence).

Because of their innate proteolytic activity, papain and bromelain have been used extensively in the food and medical industries. Both enzymes are included on the FDA's "Generally Recognized as Safe" (GRAS) list.

Potency Measurement

When purchasing proteolytic enzyme supplements, it is important to look for information about potency. Some brands only list the weight of each enzyme in milligrams, which doesn't inform the purchaser about the potency. Suggested potency levels depend on the enzyme and are still highly debated. However, trustworthy brands will list activity units, and you can compare the activity units for a particular enzyme between brands. Common activity labeling units for proteolytic enzymes include HUT, USP and SAP.

Traditional and Historical Use

Papain has been used for meat-tenderizing and folk medicine for centuries. Ancient — pre-19th century: Traditional use in tropical regions to tenderize meat and as topical poultices for wounds.

Papain has been used for thousands of years as a meat tenderizer due to its ability to break down protein. Indigenous peoples of Central and South America, where the papaya tree is native, wrapped meats in papaya leaves or rubbed them with latex from unripe fruit as a tenderizing technique — a practice that preceded any biochemical understanding of enzymatic activity.

Both bromelain and papain are used commercially for tenderizing meat and producing protein hydrolysates.

Ethnobotanically, papaya latex and leaf preparations have been employed across multiple tropical cultures — including in Central America, South and Southeast Asia, and sub-Saharan Africa — for a range of purposes including topical wound treatment, digestive complaints, intestinal parasites, and skin conditions. These uses predate modern pharmacological investigation and are documented in the ethnobotanical literature, though they reflect traditional empirical knowledge rather than controlled clinical evidence.

In the 19th century, chemical investigations identified proteolytic activity in papaya latex, and early industrial use in food processing began. In the 1920s–1950s, isolation and purification protocols were developed and enzyme assays standardized. In the 1950s–1970s, the catalytic cysteine was identified and structure–function relationships clarified. From the 1980s–2000s, papain was included in topical debriding products (papain–urea), and recombinant expression was explored.

Other uses of these enzymes have included their incorporation into toothpaste (papain/bromelain combination as the active ingredient) for extrinsic enamel stain removal.

Key Constituents and Mechanisms of Action

Proteolytic (Protein-Hydrolyzing) Activity

Proteolytic enzymes (proteases) are enzymes that break down protein. These enzymes are made by animals, plants, fungi, and bacteria. Proteolytic enzymes break down proteins in the body or on the skin. This might help with digestion or with the breakdown of proteins involved in swelling and pain.

These proteolytic enzymes have a broad range of substrate specificity, which easily and efficiently hydrolyze most soluble proteins, yielding peptides and amino acids byproducts.

Digestive Mechanism

Proteolytic enzymes (proteases) help the body digest the proteins in food. Although the body produces these enzymes in the pancreas, certain foods also contain proteolytic enzymes. Papaya and pineapple are two of the richest plant sources, as attested by their traditional use as natural tenderizers for meat. Papain and bromelain are proteolytic enzymes found in these fruits.

People do not need proteolytic enzymes from food because the body manufactures them (primarily trypsin and chymotrypsin). Supplementation is therefore most relevant in the context of insufficient endogenous enzyme production.

Anti-inflammatory and Systemic Mechanisms

The primary use of proteolytic enzymes is as a digestive aid for people who have trouble digesting proteins. However, proteolytic enzymes may also be absorbed internally to some extent and may reduce pain and inflammation.

The mechanism of action of OTC enzymes is not entirely clear as there are a number of studies demonstrating both pro-inflammatory and anti-inflammatory effects.

Wound Debridement Mechanism

Physiology: proteolytic digestion of fibrin, denatured collagen and slough loosens necrotic tissue to permit removal and expose viable tissue for healing. Molecular mechanism: papain hydrolyzes peptide bonds in extracellular proteins, reducing eschar cohesion. Target population: chronic wounds with slough/eschar (pressure ulcers, venous ulcers) where surgical debridement is contraindicated.

The effective enzymatic digestion of extracellular matrix for the preparation of cell cultures paved the way to its application for skin treatment and wound debridement. Proteases, such as papain and collagenase, mostly formulated as ointments, were successfully employed for wound debridement, achieved within several days of repeated treatments.

In Vitro Anti-Angiogenic Activity

A 2013 in vitro study published in PubMed investigated papain's effect on VEGF-activated human umbilical vein endothelial cells (HUVEC). Papain showed a strong anti-angiogenic effect in VEGF activated HUVEC. This effect may be due to interference with AKT, MEK1/2 and SAPK/JNK phosphorylation. These findings indicate that plant proteolytic enzymes may have potential as preventive and therapeutic agents against angiogenesis related human diseases. These results are preliminary and exclusively in vitro; no human clinical translation has been established.

Scientific Evidence by Area of Application

1. Digestive Support

As a therapeutic supplement, proteolytic enzymes are primarily used to aid digestion, particularly for individuals experiencing protein digestion difficulties due to pancreatic insufficiency or other gastrointestinal disorders.

The physiological rationale is well established: papain's broad-spectrum proteolytic activity supplements endogenous gastric and pancreatic proteases in the digestion of dietary protein. However, human clinical evidence specifically isolating the contribution of papain (as opposed to multi-enzyme blends) is limited. The strongest clinical rationale for papain is topical enzymatic debridement; oral digestive aid claims have weaker clinical evidence and are supported primarily by physiological plausibility and small studies.

Evidence strength: Weak to preliminary for isolated papain; physiologically plausible. Clinical benefit has not been established in robust, well-controlled human trials for papain alone.

2. Topical Wound Debridement

These enzymes have also been used for wound debridement for damaged collagen and necrotic tissue in humans.

The two most used proteolytic agents are papain and collagenase. The application of both ointments (Accuzyme® and Noruxol®, respectively) has been incorporated into the treatment regimen of burn injuries and chronic wounds with beneficial effect. Papain, derived from Carica papaya, is part of nonselective preparations. Papain–urea is mainly used to solubilize fibrin.

A clinical study in patients with large burn wounds found that papain–urea debridement was effective in removing dead tissue and generally safe when used properly, though careful monitoring was required. Regulatory policies have since tightened in some countries due to concerns about unapproved topical papain formulations and rare severe reactions. Today, enzymatic debridement using papain is typically restricted to specific products and specialist settings, if used at all.

Comparative studies of enzymatic debriding ointments have yielded a hierarchy of efficacy: comparative studies on the efficacy of wound debridement by enzyme-containing ointments indicated efficacy dependence on the enzyme employed: while fibrinolysin ointment was found ineffective, collagenase ointment gave some improvement, and papain-urea ointment was identified as most effective from this group. Prolonged time was required for these treatments to deliver significant improvement, ranging from four days to three weeks with daily wound treatments.

Papain (an enzyme from the latex of Carica papaya) is an interesting natural bioactive macromolecule used as a therapeutic alternative for wound healing due to debridement action in devitalized or necrotic tissues. However, its use in high doses can induce potential skin irritation and side effects.

Evidence strength: Moderate. Supported by clinical studies and comparative trials demonstrating debridement efficacy for papain-urea formulations; however, RCT evidence is limited and regulatory status for topical formulations varies by jurisdiction.

3. Musculoskeletal Pain and Inflammation

Beyond digestive support, proteolytic enzymes have been explored for various therapeutic applications, including relief from chronic musculoskeletal pain, osteoarthritis, and post-surgical recovery. Some studies suggest potential benefits for sports injuries and inflammation, but results have varied widely, with many studies lacking robust design or placebo controls.

In small human trials, oral proteolytic enzyme combinations that include papain have been investigated for post-surgical swelling and pain, as well as soft-tissue injuries. It is important to note that virtually all of these human trials study multi-enzyme combinations rather than papain in isolation, which makes attributing effects specifically to papain problematic.

Evidence strength: Preliminary to weak. Most evidence derives from multi-enzyme combination products, not papain alone. Study quality is generally low, with small sample sizes and variable placebo control.

4. Dental Applications (Tooth Whitening and Caries)

The use of proteolytic enzymes, such as bromelain and papain, can provide promising results for solving two important aspects related to dental aesthetics: tooth whitening and the chemo-mechanical removal of damaged dental tissue. Due to their ability to degrade salivary proteins, these enzymes can be used successfully as active agents in tooth whitening and in the atraumatic treatment of caries without being accompanied by other side effects on dental components.

A 2024 PMC literature review with meta-analyses was performed examining bromelain and papain used in dentistry. Papain is available as a supplement, as a topical application, or in combination with bromelain. It has antibacterial, anti-inflammatory, antioxidant, antiviral, antitumor, and cicatrizing properties.

Evidence strength: Moderate for dental applications. Published meta-analyses support use of papain-containing preparations in tooth whitening and atraumatic caries removal; however, this is topical/dental use, not oral supplementation.

5. Atopic Skin Inflammation

A 2024 study (PMID: 39199175) published in Antioxidants (Basel) examined papain's effects on skin inflammation. Papain suppresses atopic skin inflammation through anti-inflammatory activities using in vitro and in vivo models. These results are based on laboratory and animal models; human clinical trials in atopic dermatitis specifically for papain supplementation are not yet established.

Evidence strength: Preliminary; in vitro and animal model data only as of the available literature.

6. Chemonucleolysis (Spinal Disc Treatment)

Papain (specifically chymopapain, a related enzyme from the same plant) was historically used in a medical procedure called chemonucleolysis — intradiscal injection for the treatment of herniated intervertebral discs. Twenty-nine patients with cervical osteochondrosis and reflex syndromes were treated by the method of disc puncture using the proteolytic enzyme papain in complex with dereception. Analysis of the immediate and late results showed improvement in 74% of patients. The outcomes were determined to a certain measure by the correct choice of patients to be treated with this method. Bone growths causing compression syndromes are not resorbed by the enzyme and the method is therefore not indicated for this category of patients.

This represents a historical clinical application that is distinct from oral supplementation and is not a current standard of care in most jurisdictions.

Evidence strength: Historical clinical data; not relevant to oral dietary supplementation.

Body Systems and Health Areas

• Digestive system: Primary supplemental application — support of protein digestion, particularly in the context of reduced endogenous protease production.
• Musculoskeletal system: Investigated (in multi-enzyme combinations) for joint pain, post-surgical swelling, and soft-tissue injury recovery.
• Integumentary system (skin/wound healing): Topical enzymatic debridement of necrotic tissue in chronic wounds and burns; experimental wound-healing applications.
• Oral/dental: Teeth whitening; chemo-mechanical caries removal in dental preparations.
• Immune/inflammatory: Anti-inflammatory properties explored in vitro and in animal models; clinical evidence in humans is limited.
• Cardiovascular (in vitro/preclinical): Proteases have anti-inflammatory activity, inhibit platelet aggregation, and inhibit prostaglandins. These effects have been documented in laboratory settings for the protease class; human cardiovascular clinical evidence is not established for papain alone.

Dosage Forms and Reported Dosages

Because "Prolase" is a supplement label ingredient name, its dosage as such is not defined by any pharmacopeia or clinical guideline. The following dosages are those reported in product labeling and in the scientific/clinical literature for papain-based preparations as a class.

Activity-Based Potency

Enzyme potency in dietary supplements is expressed in activity units rather than mass, reflecting actual catalytic capacity. Common activity labeling units for proteolytic enzymes include HUT, USP and SAP. Papain is standardized in Papain Units (PU); a product example in published literature referenced 10,077,000 PU of papain per serving in a multi-enzyme formulation.

Oral Supplement Dosages from Labeled Products

• Chewable papaya enzyme tablets: labeled doses of 6 mg papaya-derived enzyme per tablet, with suggested use of three to nine tablets daily.
• Standard capsule formulations: one capsule (250 mg) of papain per serving, used up to three times daily with food.
• Multi-enzyme combinations containing papain: 3 capsules daily away from food (one hour before or two hours afterwards), or as recommended by a healthcare professional.

Topical Formulations

Topical papain-urea ointments used in clinical wound debridement are distinct products from oral supplements and are used under medical supervision; their dosing is not applicable to the dietary supplement context. Visible softening/partial debridement often occurs within 24–72 hours of appropriate topical application; full debridement depends on necrotic burden and frequency of dressing changes.

Timing Considerations

The purpose of administration influences timing: most supplements should be taken around twenty minutes before meals for best results when used for digestive support. For systemic anti-inflammatory effects, some product labels recommend administration between meals or away from food to maximize systemic absorption rather than luminal digestive activity.

Safety Considerations and Interactions

Regulatory GRAS Status (USA)

Because of their innate proteolytic activity, papain and bromelain have been used extensively in the food and medical industries. Both enzymes are included on the FDA's "Generally Recognized as Safe" (GRAS) list.

EFSA Safety Assessment

The European Food Safety Authority (EFSA) has conducted multiple formal safety evaluations of papain as a food enzyme. The Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded. Based on the data provided, the origin of the food enzyme being an edible plant source and the estimated dietary exposure, the Panel concluded that the food enzyme does not give rise to safety concerns under the intended conditions of use.

Allergenicity

Allergenicity is the most formally documented safety concern for papain-based preparations. Among the four proteins in the cysteine endopeptidase complex, papain and chymopapain are known food allergens. Homology searches of the amino acid sequences of the four proteins in the complex to known allergens identified matches with six food and eight respiratory allergens. The Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded.

The matching respiratory allergens were group 1 mite allergens (36.3%–48.8% sequence identity), cysteine proteases from Dermatophagoides pteronyssinus, Dermatophagoides farinae, and other mite species. Der p 1 and Der f 1 are major mite allergens associated with rhinitis and asthma. No evidence of papain-related allergic reactions upon dietary exposure in individuals sensitised to mites is available. The Panel considered that the results of the sequence homology search and the available literature indicate a risk of allergic reactions for papaya, ananas, kiwi, soy, fig and pollen allergic individuals upon dietary exposure.

Occupational/Inhalation Risk

Industrial handling of papain powder carries a documented occupational inhalation sensitization risk. A 1982 clinical study (Baur et al., cited in EFSA 2026) involving thirty-three papain workers documented "strong immunogenic potency and clinically relevant proteolytic effects of airborne papain" on the basis of skin test, RAST, and bronchial provocation test results. This risk applies to occupational inhalation exposure and not typically to oral dietary supplement consumers.

Topical Safety at High Doses

Papain (an enzyme from the latex of Carica papaya) is an interesting natural bioactive macromolecule used as a therapeutic alternative for wound healing due to debridement action in devitalized or necrotic tissues. However, its use in high doses can induce potential skin irritation and side effects.

Regulatory policies have tightened in some countries due to concerns about unapproved topical papain formulations and rare severe reactions. Today, enzymatic debridement using papain is typically restricted to specific products and specialist settings, if used at all.

Drug Interactions

Proteases have anti-inflammatory activity, inhibit platelet aggregation, and inhibit prostaglandins. Because of demonstrated platelet aggregation inhibition, papain-containing preparations carry a theoretical interaction risk with anticoagulant and antiplatelet medications (e.g., warfarin, aspirin, clopidogrel). This interaction has been documented in the context of the broader protease class in the clinical literature.

Long-Term Safety

These proteases have been in clinical use for over 30 years and have no harmful side effects even with prolonged use, according to one patent-based clinical summary. This claim, however, pertains to multi-enzyme blends at conventional supplemental doses, and should be interpreted in the context that robust long-term RCT data for papain specifically are lacking.

Pregnancy, Lactation, and Special Populations

The EFSA safety opinions reviewed did not address pregnancy or lactation specifically in the context of dietary supplementation. The safety of papain-based supplements during pregnancy has not been established in controlled human studies, a limitation that should be noted from the available regulatory record.

Evidence Summary

The table below summarizes the strength of evidence for principal applications of papain-containing preparations (including those marketed as Prolase):

• Topical wound debridement: Moderate evidence; supported by clinical studies and comparative trials, with regulatory-approved products historically available. Current use restricted to specialist settings in many jurisdictions.
• Digestive enzyme supplementation: Weak clinical evidence for papain alone; physiological rationale is plausible; most human data are from multi-enzyme combinations.
• Musculoskeletal pain/inflammation: Preliminary; multi-enzyme combination data only; lacks papain-specific RCTs.
• Dental whitening/caries: Moderate; meta-analytic data support topical dental applications.
• Anti-angiogenic/skin inflammatory: Preliminary; in vitro and animal data only.

As documented in the EBSCO Research Starters Biology series: beyond digestive support, proteolytic enzymes have been explored for various therapeutic applications, including relief from chronic musculoskeletal pain, osteoarthritis, and post-surgical recovery. Some studies suggest potential benefits for sports injuries and inflammation, but results have varied widely, with many studies lacking robust design or placebo controls.

References

• NIH Office of Dietary Supplements — Dietary Supplement Label Database (DSLD): Prolase Ingredient Entry
• EFSA Journal (2026) — Safety evaluation of the food enzyme papain from the latex of Carica papaya L. (Nagase Europe)
• PMC / EFSA Journal (2026) — Safety evaluation of the food enzyme papain, a cysteine endopeptidase complex from the latex of Carica papaya L. (Enzybel International SA)
• PMC / EFSA Journal (2026) — Safety evaluation of the food enzyme papain, a cysteine endopeptidase complex from the latex of Carica papaya L. (Troplandis BVBA)
• EBSCO Research Starters — Proteolytic Enzymes as a Therapeutic Supplement
• Mayo Clinic Proceedings (2014) — Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know
• PubMed (2013) — Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro
• PubMed (1986) — Use of the proteolytic enzyme papain in the treatment of cervical osteochondrosis
• PMC (2024) — Effects of Bromelain and Papain in Tooth Whitening and Caries Removal: A Literature Review
• PMC (2024) — Immobilization of Papain in Chitosan Membranes as a Potential Alternative for Skin Wounds
• ClinicalTrials.gov — Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse (Protocol/SAP)
• PubMed (2015) — Wound Debridement by Continuous Streaming of Proteolytic Enzyme Solutions: Effects on Experimental Chronic Wound Model in Porcine
• PMC — Hyaluronic Acid/Collagenase Ointment in the Treatment of Chronic Hard-to-Heal Wounds
• Enzyme Development Corporation — Papain Production and Industrial Applications
• DietarySupplementDB — Papain: Complete Science-Based Guide 2026
• Cosmetic Ingredient Review (CIR) — Safety Assessment of Carica papaya (Papaya)-Derived Ingredients
• NIH Office of Dietary Supplements — About the Dietary Supplement Label Database (DSLD)